Phase II study Systemic treatment with ZK219477 EPOTHILONE in recurrent Glioblastoma patients

Registry ID

EUCTR2005-005877-31

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

ISTITUTO NEUROLOGICO CARLO BESTA

Start date

2006-03-27

Completion date

2008-03-05

Last update

2026-08-16

Conditions

• Recurrent Glioblastoma

Summary

To evaluate safety and efficacy of ZK219477 in the treatment of pre-treated, recurrent GBM patients. An optional PK study will be performed in selected patients.

Locations

• , , Italy

Related clinical trials

• Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
• Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
• Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
• A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
• A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

View on source registry